{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-25-000099","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.805301+00:00","generated_at":"2026-05-17T19:39:10.150639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus Biosciences Q2 2025 rev $160M (incl $143M one-time), net income breakeven; casdatifan Phase 3 trials initiated","bullets":["Cash, cash equivalents & marketable securities: $927M at June 30, 2025 (Dec 31, 2024: $992M).","Q2 2025 revenue $160M vs $39M YoY, driven by $143M cumulative catch-up from etrumadenant program pause.","R&D expenses $139M (vs $115M Q2 2024); CMC costs expected elevated through Q3, then decline from Q4.","PEAK-1 (Phase 3 casdatifan + cabozantinib) and eVOLVE-RCC02 (Phase 1b/3 with AstraZeneca) initiated in ccRCC.","Quemliclustat granted FDA Orphan Drug Designation for pancreatic cancer; PRISM-1 enrollment completion expected Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-25-000099","json":"https://secwatch.observer/filing/0001724521-25-000099.json","markdown":"https://secwatch.observer/filing/0001724521-25-000099.md","text":"https://secwatch.observer/filing/0001724521-25-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000099/0001724521-25-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000099/rcus-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:39:10.150639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}